SYHA 1908
Alternative Names: SYHA-1908Latest Information Update: 31 May 2023
At a glance
- Originator CSPC Pharmaceutical Group
- Class Antineoplastics; Protein-drug conjugates; Small molecules; Taxanes
- Mechanism of Action Microfilament protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 May 2023 Preclinical trials in Solid tumours in China (unspecified route) (CSPC Pharmaceutical Group pipeline, May 2023)